nach oben

Molecular Imaging and Biology

Erschienen in:

01.06.2018 | Brief Article

MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([¹⁸F]-AV-1451) Binding

verfasst von: Allan K. Hansen, David J. Brooks, Per Borghammer

Erschienen in: Molecular Imaging and Biology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Recent evidence suggests that the tau radiotracer [¹⁸F]THK-5351 displays high affinity for the monoamine oxidase type B (MAO-B) enzyme. Utilizing another tau-tracer, flortaucipir ([¹⁸F]AV-1451), we previously reported that non-demented Parkinson’s disease patients show off-target binding in subcortical structures, but no appreciable cortical uptake. However, 59 % of these patients were receiving MAO-B inhibitors at the time of their scan. Here, we retrospectively investigated if MAO-B inhibitors in clinical doses affect flortaucipir binding.

Procedures

We compared the standard uptake values of flortaucipir at regional and voxel levels in Parkinson’s disease patients who received MAO-B inhibitors with those who did not.

Results

Sixteen of 27 Parkinson’s disease patients received MAO-B inhibitors at the time of scan. We found no significant flortaucipir uptake differences between the groups at voxel or regional levels.

Conclusion

Use of MAO-B inhibitors at pharmaceutical levels did not significantly affect flortaucipir binding. Thus, MAO-B does not appear to be a significant binding target of flortaucipir.

Johnson KA, Schultz A, Betensky RA et al (2016) Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79:110–119PubMedCrossRef

Schöll M, Lockhart SN, Schonhaut DR et al (2016) PET imaging of tau deposition in the aging human brain. Neuron 89:971–982PubMedPubMedCentralCrossRef

Cho H, Choi JY, Hwang MS et al (2016) Tau PET in Alzheimer disease and mild cognitive impairment. Neurology 87:375–383PubMedCrossRef

Pontecorvo MJ, Devous MD, Navitsky M et al (2017) Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140:748–763PubMedPubMedCentral

Hansen AK, Knudsen K, Lillethorup TP et al (2016) In vivo imaging of neuromelanin in Parkinson’s disease using 18F-AV-1451 PET. Brain 139:2039–2049PubMedCrossRef

Passamonti L, Vázquez Rodríguez P, Hong YT et al (2017) ¹⁸F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy. Brain 140:781–791PubMedPubMedCentral

Marquié M, Normandin MD, Vanderburg CR et al (2015) Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78:787–800PubMedPubMedCentralCrossRef

Ng KP, Pascoal TA, Mathotaarachchi S et al (2017) Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther 9:25PubMedPubMedCentralCrossRef

Carter SF, Scholl M, Almkvist O et al (2012) Evidence for Astrocytosis in prodromal Alzheimer disease provided by ¹¹C-deuterium-L-Deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and ¹⁸F-FDG. J Nucl Med 53:37–46PubMedCrossRef

10.

Tong J, Meyer JH, Furukawa Y et al (2013) Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab 33:863–871PubMedPubMedCentralCrossRef

11.

Hansen AK, Damholdt MF, Fedorova TD et al (2017) In vivo cortical tau in Parkinson’s disease using ¹⁸F-AV-1451 positron emission tomography. Mov Disord 32:922–927PubMedCrossRef

12.

Xia CF, Arteaga J, Chen G et al (2013) [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement 9:666–676PubMedCrossRef

13.

Vermeiren C, Mercier J, Viot D et al (2015) T807, a reported selective tau tracer, binds with nanomolar affinity to monoamine oxidase a. Alzheimers Dement 11:P283CrossRef

14.

Lowe VJ, Curran G, Fang P et al (2016) An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun 4:58PubMedPubMedCentralCrossRef

15.

Marquié M, Normandin MD, Meltzer AC et al (2017) Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol 81:117–128PubMedPubMedCentralCrossRef

16.

Smith R, Schöll M, Honer M et al (2017) Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Acta Neuropathol 133:149–151PubMedCrossRef

17.

Nag S, Fazio P, Lehmann L et al (2016) In vivo and in vitro characterization of a novel MAO-B inhibitor Radioligand, 18F-labeled deuterated Fluorodeprenyl. J Nucl Med 57:315–320PubMedCrossRef

18.

Lockhart SN, Baker SL, Okamura N et al (2016) Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer’s disease patients measured using [18F] THK-5351. PLoS One 11:1–16CrossRef

19.

Ikonomovic MD, Abrahamson EE, Price JC et al (2016) [F-18]AV-1451 positron emission tomography retention in choroid plexus: more than “off-target” binding. Ann Neurol 80:307–308PubMedPubMedCentralCrossRef

20.

Cho H, Choi JY, Hwang MS et al (2017) Subcortical ¹⁸F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord 32:134–140PubMedCrossRef

21.

Whitwell JL, Lowe VJ, Tosakulwong N et al (2017) [¹⁸F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord 32:124–133PubMedCrossRef

22.

Smith R, Schain M, Nilsson C et al (2017) Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord 32:108–114PubMedCrossRef

23.

Cho H, Choi JY, Lee SH et al (2017) ¹⁸F-AV-1451 binds to putamen in multiple system atrophy. Mov Disord 32:171–173PubMedCrossRef

24.

Shcherbinin S, Schwarz AJ, Joshi A et al (2016) Kinetics of the tau PET tracer ¹⁸F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment, and Alzheimer disease. J Nucl Med 57:1535–1542PubMedCrossRef

25.

Zecca L, Fariello R, Riederer P et al (2002) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson’s disease. FEBS Lett 510:216–220PubMedCrossRef

26.

Zecca L, Bellei C, Costi P et al (2008) New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc Natl Acad Sci U S A 105:17567–17572PubMedPubMedCentralCrossRef

27.

Fowler JS, Logan J, Wang G-J, Volkow ND (2003) Monoamine oxidase and cigarette smoking. Neurotoxicology 24:75–82PubMedCrossRef

28.

Nakamura S, Kawamata T, Akiguchi I et al (1990) Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol 80:419–425PubMedCrossRef

29.

Fowler JS, Volkow ND, Wang GJ et al (1996) Brain monoamine oxidase a inhibition in cigarette smokers. Proc Natl Acad Sci U S A 93:14065–14069PubMedPubMedCentralCrossRef

30.

Fowler JS, MacGregor RR, Wolf AP et al (1987) Mapping human brain monoamine oxidase A and B with ¹¹C-labeled suicide inactivators and PET. Science 235:481–485PubMedCrossRef

31.

Jensen SB, Olsen AK, Pedersen K, Cumming P (2006) Effect of monoamine oxidase inhibition on amphetamine-evoked changes in dopamine receptor availability in the living pig: a dual tracer PET study with [¹¹C]harmine and [¹¹C]raclopride. Synapse 59:427–434PubMedCrossRef

32.

Ginovart N, Meyer JH, Boovariwala A et al (2006) Positron emission tomography quantification of [¹¹C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab 26:330–344PubMedCrossRef

33.

Fowler JS, Volkow ND, Logan J et al (1994) Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. Synapse 18:86–93PubMedCrossRef

34.

Arnett CD, Fowler JS, MacGregor RR et al (1987) Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[¹¹C]deprenyl. J Neurochem 49:522–527PubMedCrossRef

35.

Lemoine L, Saint-Aubert L, Nennesmo I et al (2017) Cortical laminar tau deposits and activated astrocytes in Alzheimer’s disease visualised by ³H-THK5117 and 3H-deprenyl autoradiography. Sci Rep 7:45496PubMedPubMedCentralCrossRef

Titel: MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding
verfasst von: Allan K. Hansen
David J. Brooks
Per Borghammer
Publikationsdatum: 01.06.2018
Verlag: Springer International Publishing
Erschienen in: Molecular Imaging and Biology / Ausgabe 3/2018
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-017-1143-1

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([¹⁸F]-AV-1451) Binding

Abstract

Purpose

Procedures

Results

Conclusion

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Procedures

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Assessing Glomerular Filtration in Small Animals Using [68Ga]DTPA and [68Ga]EDTA with PET Imaging

Optimization of Dendritic Cell-Mediated Cytotoxic T-Cell Activation by Tracking of Dendritic Cell Migration Using Reporter Gene Imaging

Metformin Promotes 2-Deoxy-2-[18F]Fluoro-D-Glucose Uptake in Hepatocellular Carcinoma Cells Through FoxO1-Mediated Downregulation of Glucose-6-Phosphatase

Upregulated Sphingosine 1-Phosphate Receptor 1 Expression in Human and Murine Atherosclerotic Plaques

Single-Cell Imaging Using Radioluminescence Microscopy Reveals Unexpected Binding Target for [18F]HFB

Response to Notter and Meyer’s Letter to the Editor Regarding Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Update Radiologie